Olmesartan Medoxomil

CAS 144689-63-4 37 current records 12 historicalSmall Molecule

Who holds supplier records for Olmesartan Medoxomil? 37 organisations hold a current record for Olmesartan Medoxomil: an active US FDA Type II Drug Master File or a CEP. A further 12 organisations have only historical (inactive) DMF filings. 31 of them hold a valid EU Certificate of Suitability (32 holder entries on the EDQM register, listed below). Recorded organisation countries for current records: India (23), China (8), Hungary (1), Netherlands (1) and 3 other countries (3); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Olmesartan Medoxomil: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/olmesartan-medoxomil

Reading the evidence

  • 37 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    23 of the 36 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 17 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (37)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Olmesartan Medoxomil. Country is the organisation's recorded country, not necessarily the manufacturing site.

India23China8Hungary1Netherlands1South Korea1Spain1Slovenia1Country not recorded for 1
Need Olmesartan Medoxomil sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (32)

Certificates of Suitability on the EDQM register for Olmesartan Medoxomil, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 54 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
MATRIX PHARMACORP PRIVATE LIMITED SangareddyIN
CEP 2012-043 - Rev 06
Olmesartan medoxomil
Sept 2026—
MACLEODS PHARMACEUTICALS LIMITED MumbaiIN
CEP 2014-196 - Rev 04
Olmesartan medoxomil
Sept 2026—
VIYASH SCIENTIFIC LIMITED HyderabadIN
CEP 2023-253 - Rev 02
Olmesartan medoxomil
Jul 2026—
TORRENT PHARMACEUTICALS LIMITED AhmedabadIN
CEP 2023-126 - Rev 01
Olmesartan medoxomil
Jul 2026—
APITORIA PHARMA PRIVATE LIMITED HyderabadIN
CEP 2020-112 - Rev 05
Olmesartan medoxomil, Process II
Jul 2026—
AMOLI ORGANICS PRIVATE LIMITED MumbaiIN
CEP 2026-148 - Rev 00
Olmesartan medoxomil, Process-III
Jun 2026—
ZHUHAI RUNDU PHARMACEUTICAL CO., LTD. ZhuhaiCN
CEP 2026-083 - Rev 00
Olmesartan medoxomil, Process 2
Jun 2026—
ALIVUS LIFE SCIENCES LIMITED MumbaiIN
CEP 2012-228 - Rev 03
Olmesartan medoxomil
May 2026—
CHIERON ACTIVE INGREDIENTS PRIVATE LIMITED HyderabadIN
CEP 2018-232 - Rev 03
Olmesartan medoxomil
Apr 2026—
DONGBANG FUTURE TECH & LIFE CO., LTD. Hwaseong-SiKR
CEP 2015-237 - Rev 02
Olmesartan medoxomil
Mar 2026—
YANTAI VALIANT PHARMACEUTICAL CO. LTD. YantaiCN
CEP 2024-350 - Rev 01
Olmesartan medoxomil, Micronised
Feb 2026—
ALEMBIC PHARMACEUTICALS LIMITED VadodaraIN
CEP 2013-297 - Rev 02
Olmesartan medoxomil
Jan 2026—
CPL PHARMACEUTICALS PRIVATE LIMITED AhmedabadIN
CEP 2025-511 - Rev 00
Olmesartan medoxomil, Process-II, Micronised, non-micronised
Jan 2026—
JUBILANT BIOSYS LIMITED MysuruIN
CEP 2013-325 - Rev 02
Olmesartan medoxomil
Jan 2026—
EUROAPI HUNGARY Ltd. BudapestHU
CEP 2013-105 - Rev 04
Olmesartan medoxomil
Jun 2025Inspected Jul 2026
Hungary
CHROMO LABORATORIES INDIA PRIVATE LIMITED PashamylaramIN
CEP 2018-083 - Rev 04
Olmesartan medoxomil
Apr 2025—
HETERO LABS LIMITED HyderabadIN
CEP 2024-040 - Rev 00
Olmesartan medoxomil, OQ process, crystalline form
Mar 2025—
TAPI NL B.V. AmsterdamNL
CEP 2012-170 - Rev 02
Olmesartan medoxomil
Mar 2025—
ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD. Taizhou CityCN
CEP 2013-268 - Rev 03
Olmesartan medoxomil
Mar 2025—
MSN LABORATORIES PRIVATE LIMITED Rudraram VillageIN
CEP 2012-070 - Rev 02
Olmesartan medoxomil, Micronised and non-micronised
Mar 2025—
HEC PHARM CO., LTD. Yidu CityCN
CEP 2016-032 - Rev 02
Olmesartan medoxomil
Jan 2025Inspected Nov 2025
Germany
CADILA PHARMACEUTICALS LIMITED AnkleshwarIN
CEP 2022-427 - Rev 00
Olmesartan medoxomil
Sept 2024—
MOREPEN LABORATORIES LIMITED BaddiIN
CEP 2021-485 - Rev 00
Olmesartan medoxomil
Sept 2024Inspected Mar 2026
Spain
VASUDHA PHARMA CHEM LIMITED HyderabadIN
CEP 2015-076 - Rev 03
Olmesartan medoxomil
Aug 2024—
ZYDUS LIFESCIENCES LIMITED VadodaraIN
R1-CEP 2015-383 - Rev 00
Olmesartan medoxomil
Feb 2023—
MICRO LABS LIMITED BengaluruIN
R1-CEP 2014-251 - Rev 01
Olmesartan medoxomil
Jan 2023—
Interquim, S.A. Sant Cugat Del VallèsES
R1-CEP 2014-295 - Rev 01
Olmesartan medoxomil
Dec 2022—
ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. LinhaiCN
R0-CEP 2022-194 - Rev 00
Olmesartan medoxomil, Process II
Sept 2022—
SECOND PHARMA CO., LTD. Shangyu CityCN
R1-CEP 2014-322 - Rev 01
Olmesartan medoxomil
May 2022—
SHANDONG ANXIN PHARMACEUTICAL CO., LTD. Dongjia TownCN
R1-CEP 2014-225 - Rev 00
Olmesartan medoxomil
Jan 2022—
KRKA, d.d., Novo mesto Novo mestoSI
R1-CEP 2015-259 - Rev 00
Olmesartan medoxomil
Sept 2021—
ZHUHAI RUNDU PHARMACEUTICAL CO., LTD. Sanzao TownCN
R1-CEP 2014-121 - Rev 01
Olmesartan medoxomil
Jan 2021—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (12)

Organisations whose Type II DMFs for Olmesartan Medoxomil are no longer active. These show a past filing, not current supply.

Show all 12 historical records
  • India · Inactive DMF 30433 · filed Mar 2016
  • India · Inactive DMF 29026 · filed Feb 2015
  • India · Inactive DMF 26782 · filed Apr 2013
  • QILU TIANHE PHARMACEUTICAL CO LTD
    Inactive DMF 26420 · filed Sept 2012
  • India · Inactive DMF 26198 · filed Jul 2012
  • Apotex Pharmachem India Pvt. Ltd.
    India · Inactive DMF 25494 · filed Nov 2011
  • RANBAXY LABORATORIES LTD
    Inactive DMF 24432 · filed Dec 2010
  • India · Inactive DMF 19384, 23658 · filed Mar 2010
  • India · Inactive DMF 23617 · filed Mar 2010
  • Amino Chemicals Ltd
    Malta · Inactive DMF 22721 · filed Apr 2009
  • Japan · Inactive DMF 14953 · filed Jul 2000
  • Sankyo
    Inactive DMF 11433 · filed Apr 1995

Overview

Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) used to treat high blood pressure by relaxing blood vessels so that blood can flow more easily. It helps prevent strokes, heart attacks, and kidney problems by reducing the risk of cardiovascular events.

Chemical identity

IUPAC name
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
Canonical SMILES
CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O
InChIKey
UQGKUQLKSCSZGY-UHFFFAOYSA-N
Synonyms
Benicar API, azor component olmesartan medoxomil, benicar, cs-866, nsc-758924, olmetec, tribenzor component olmesartan medoxomil

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Angiotensin 2 Receptor Blocker
Mechanism of action
Angiotensin 2 Receptor Antagonists

Therapeutic areas

CardiovascularHypertensionHeart Failure

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Olmesartan Medoxomil?

37 organisations hold an active US FDA Type II Drug Master File or a CEP for Olmesartan Medoxomil: APITORIA PHARMA PRIVATE LTD (India), Alembic Pharmaceuticals Limited (India), ALIVUS LIFE SCIENCES LTD (India), Cadila Pharmaceuticals Limited (India), CHIERON ACTIVE INGREDIENTS PRIVATE LTD (India), CHROMO LABORATORIES INDIA PRIVATE LTD (India), EUROAPI HUNGARY LTD (Hungary) and Hetero Labs Limited (India), and 29 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Olmesartan Medoxomil Drug Master Files are active?

APITORIA PHARMA PRIVATE LTD (DMF 26035, 40890), Alembic Pharmaceuticals Limited (DMF 24671), ALIVUS LIFE SCIENCES LTD (DMF 19141), Cadila Pharmaceuticals Limited (DMF 22861), CHIERON ACTIVE INGREDIENTS PRIVATE LTD (DMF 23153), CHROMO LABORATORIES INDIA PRIVATE LTD (DMF 33587), EUROAPI HUNGARY LTD (DMF 28444) and Hetero Labs Limited (DMF 26992) and 21 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Olmesartan Medoxomil records mean?

12 organisations have only inactive Type II DMFs for Olmesartan Medoxomil. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Olmesartan Medoxomil have a European Certificate of Suitability?

Yes. 31 organisations hold a valid CEP for Olmesartan Medoxomil on the EDQM register, including MATRIX PHARMACORP PRIVATE LIMITED Sangareddy (IN), MACLEODS PHARMACEUTICALS LIMITED Mumbai (IN), VIYASH SCIENTIFIC LIMITED Hyderabad (IN), TORRENT PHARMACEUTICALS LIMITED Ahmedabad (IN), APITORIA PHARMA PRIVATE LIMITED Hyderabad (IN) and AMOLI ORGANICS PRIVATE LIMITED Mumbai (IN) and 26 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

How do I qualify a Olmesartan Medoxomil supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Olmesartan Medoxomil?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.